Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) FCF Margin (2016 - 2025)

Tg Therapeutics has reported FCF Margin over the past 10 years, most recently at 10.17% for Q4 2025.

  • Quarterly results put FCF Margin at 10.17% for Q4 2025, up 3389.0% from a year ago — trailing twelve months through Dec 2025 was 4.05% (up 827.0% YoY), and the annual figure for FY2025 was 4.05%, up 827.0%.
  • FCF Margin for Q4 2025 was 10.17% at Tg Therapeutics, up from 14.37% in the prior quarter.
  • Over the last five years, FCF Margin for TGTX hit a ceiling of 50.48% in Q3 2023 and a floor of 36701.06% in Q3 2022.
  • Median FCF Margin over the past 5 years was 145.68% (2023), compared with a mean of 5026.45%.
  • Biggest five-year swings in FCF Margin: soared 15337188bps in 2021 and later crashed -3338678bps in 2022.
  • Tg Therapeutics' FCF Margin stood at 3747.91% in 2021, then tumbled by -696bps to 29841.25% in 2022, then skyrocketed by 100bps to 30.04% in 2023, then grew by 21bps to 23.72% in 2024, then surged by 143bps to 10.17% in 2025.
  • The last three reported values for FCF Margin were 10.17% (Q4 2025), 14.37% (Q3 2025), and 5.24% (Q2 2025) per Business Quant data.